MedTrace Logo

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis

NCT03421431 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2021-09-16

Study results available
· View outcomes & findings →

Summary

A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with Non-Alcoholic Steatohepatitis

Conditions

  • Non-Alcoholic Steatohepatitis

Interventions

DRUG

EDP-305 Dose 1

Two tablets daily for 12 weeks

DRUG

EDP-305 Dose 2

Two tablets daily for 12 weeks

DRUG

Placebo

Two tablets daily for 12 weeks

Sponsors & Collaborators

  • ICON Clinical Research

    collaborator INDUSTRY

  • Triangle Biostatistics, LLC

    collaborator INDUSTRY

  • Enanta Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • Nathalie Adda, MD · Enanta Pharmaceuticals, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-25
Primary Completion
2019-06-14
Completion
2019-07-10
FDA Drug
Yes

Countries

  • United States
  • Canada
  • France
  • New Zealand
  • Puerto Rico
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03421431 on ClinicalTrials.gov